Literature DB >> 19532120

Role of Th17 cells in the immunopathogenesis of dry eye disease.

S K Chauhan, R Dana.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19532120      PMCID: PMC2719854          DOI: 10.1038/mi.2009.21

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


× No keyword cloud information.
  5 in total

Review 1.  Dry eye syndromes.

Authors:  Stefano Barabino; M Reza Dana
Journal:  Chem Immunol Allergy       Date:  2007

Review 2.  Epithelial-immune cell interaction in dry eye.

Authors:  Stephen C Pflugfelder; Cintia S de Paiva; De-Quan Li; Michael E Stern
Journal:  Cornea       Date:  2008-09       Impact factor: 2.651

3.  Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression.

Authors:  Sunil K Chauhan; Jaafar El Annan; Tatiana Ecoiffier; Sunali Goyal; Qiang Zhang; Daniel R Saban; Reza Dana
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

4.  IL-17 disrupts corneal barrier following desiccating stress.

Authors:  C S De Paiva; S Chotikavanich; S B Pangelinan; J D Pitcher; B Fang; X Zheng; P Ma; W J Farley; K F Siemasko; J Y Niederkorn; M E Stern; D-Q Li; S C Pflugfelder
Journal:  Mucosal Immunol       Date:  2009-02-25       Impact factor: 7.313

Review 5.  Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007).

Authors: 
Journal:  Ocul Surf       Date:  2007-04       Impact factor: 5.033

  5 in total
  41 in total

1.  sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model.

Authors:  Yi Wei; Seth P Epstein; Shima Fukuoka; Neil P Birmingham; Xiu-Min Li; Penny A Asbell
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-01       Impact factor: 4.799

2.  The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease.

Authors:  Thomas H Dohlman; Sunil K Chauhan; Shilpa Kodati; Jing Hua; Yihe Chen; Masahiro Omoto; Zahra Sadrai; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-12       Impact factor: 4.799

3.  Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures.

Authors:  Yi Wei; Neha Gadaria-Rathod; Seth Epstein; Penny Asbell
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-23       Impact factor: 4.799

Review 4.  Translational Immunoimaging and Neuroimaging Demonstrate Corneal Neuroimmune Crosstalk.

Authors:  Pedram Hamrah; Yashar Seyed-Razavi; Takefumi Yamaguchi
Journal:  Cornea       Date:  2016-11       Impact factor: 2.651

5.  Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease.

Authors:  Sunali Goyal; Sunil K Chauhan; Reza Dana
Journal:  Arch Ophthalmol       Date:  2011-09-12

Review 6.  The core mechanism of dry eye disease is inflammation.

Authors:  Yi Wei; Penny A Asbell
Journal:  Eye Contact Lens       Date:  2014-07       Impact factor: 2.018

Review 7.  Thrombospondin-1 in ocular surface health and disease.

Authors:  William Foulsham; Thomas H Dohlman; Sharad K Mittal; Yukako Taketani; Rohan Bir Singh; Sharmila Masli; Reza Dana
Journal:  Ocul Surf       Date:  2019-06-05       Impact factor: 5.033

8.  Aged Mice Exhibit Severe Exacerbations of Dry Eye Disease with an Amplified Memory Th17 Cell Response.

Authors:  William Foulsham; Sharad K Mittal; Yukako Taketani; Yihe Chen; Takeshi Nakao; Sunil K Chauhan; Reza Dana
Journal:  Am J Pathol       Date:  2020-04-11       Impact factor: 4.307

Review 9.  Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease.

Authors:  Anthony J St Leger; Rachel R Caspi
Journal:  Bioessays       Date:  2018-10-05       Impact factor: 4.345

10.  Effect of desiccating environmental stress versus systemic muscarinic AChR blockade on dry eye immunopathogenesis.

Authors:  Yihe Chen; Sunil K Chauhan; Hyun Soo Lee; William Stevenson; Chris S Schaumburg; Zahra Sadrai; Daniel R Saban; Shilpa Kodati; Michael E Stern; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-03       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.